Combined hormonal contraceptives (CHCs), according to the opinion by The Manchester International Consensus Group, should be considered for women wishing contraception because also positively impact endometrial cancer and ovarian cancer risk. The awareness of the effects of hormonal therapies in women at high risk of developing endometrial cancer, colorectal, breast, or ovarian cancer, such as those affected by Lynch syndrome (LS), is currently limited, with few published studies addressing these populations. Making informed decisions about CHC use in this context necessitates careful consideration of individual cancer risk and the potential benefits and risks associated with CHC use. Accurate information regarding the oncological risks associated with CHC use is essential for facilitating shared decision-making between women and their healthcare providers in this patient population. This prospective study aims to evaluate the knowledge, attitudes, and beliefs of women with LS concerning CHCs and their potential effects on specific disease development and cancer risk, comparing them to the general population. By considering psychosocial factors and individual perceptions of cancer risk, this study seeks to contribute to informed decision-making, personalized counseling, and improved strategies for gynecologic cancer risk management in women with LS.
Study Type
OBSERVATIONAL
Enrollment
180
This survey investigated the CHC use (type and timing of administration) and patients' perception about the relationship between CHC and cancer, diseases and symptoms
IRCCS Ospedale Policlinico San Martino
Genova, Italy
Number of patients using currently CHCs
Evaluation of the number (%) of patients using currently CHCs
Time frame: Through study completion, an average of 1 month
Number of patients having used CHCs
Evaluation of the number (%) of patients having used CHCs in the past
Time frame: Through study completion, an average of 1 month
Perception about the impact of CHCs on favoring/contrasting specific cancer onset
By using a Likert scale (from -5 to +5)
Time frame: Through study completion, an average of 1 month
Perception about the impact of CHCs on favoring/contrasting specific chronic disease onset
By using a Likert scale (from -5 to +5)
Time frame: Through study completion, an average of 1 month
Perception about the impact of CHCs on favoring/contrasting specific symptoms onset
By using a Likert scale (from -5 to +5)
Time frame: Through study completion, an average of 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.